Allogene Therapeutics
Ho Chuen Lau is a Senior Associate Scientist at Allogene Therapeutics, a position held since November 2022. Lau has also worked at Virovek, Inc. as a Senior Research Associate since August 2019 and as a Research Associate since July 2020. Prior experience includes serving as an Assistant at the UC Davis Fish Conservation and Culture Laboratory from March 2019 to July 2020. Ho Chuen Lau earned a Bachelor's degree in Animal Sciences from the University of California, Davis, from 2017 to 2019.
This person is not in the org chart
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.